Simvastatin Articles
FDA expands on cholesterol-lowering drug risks
29 February 2012
Pfizer gets US FDA approval for Prevnar 13, a Wyeth drug with blockbuster sales outlook
25 February 2010
Use of statins does increases risk of diabetes, but only by 9%, says report in Lancet
19 February 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
AstraZeneca gets wider US indications for Crestor; enters cancer drug development deal with UK charity
9 February 2010
Abbott in settlement deal with Teva over Tricor generic
1 December 2009
Merck & Co remains confident in Zetia and Vytorin, despite studying questioning the drugs
16 November 2009
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
Abbott and AZ set to co-promote TriLipix
5 June 2009
Generic drugs "saved USA $734B" since 1999, GPhA says, more than cost of TARP bank bail out
11 May 2009
Schering-Plough profits beat forecasts
21 April 2009
Solvay viewing options for pharma
2 April 2009
Study shows no higher cancer risk with Vytorin
27 March 2009
Sweden's TLV rejects 1st-line use of Pfizer's Lipitor, cites "20 times" cost differential
23 February 2009
Stock Commentary - New York week to Feb 9, 2009
16 February 2009
Stock Commentary - New York week to Feb 2, 2009
9 February 2009
US generic sales value falls, despite volume rise
19 January 2009
FDA approves Abbott's cholesterol drug
22 December 2008
English doctors face sack over non-NICE Rxing
22 December 2008
New US DTC guidelines from PhRMA dismissed by leading Democrats
22 December 2008
Pfizer study bites back against claims generic CV drugs just as effective as branded
15 December 2008
Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs
15 December 2008
Stock Commentary - New York week to Dec 1, 2008
8 December 2008
AOK tender pressure for German generic firms
8 December 2008
S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years
8 December 2008
Negative press has compromised Vytorin as first-line therapy; DR
17 November 2008
Pronova doubles 3rd-qtr profit on Omacor sales
17 November 2008
Pronova to supply Defiante with Omacor for combination product
10 November 2008
Solvay's 9-month profit down 34% on Fortis
10 November 2008
S-P profit falls 21%, still up on predictions
27 October 2008
Ranbaxy responds to FDA allegations
29 September 2008
Divided opinion on Vytorin despite
8 September 2008
FDA investigates Vytorin link to cancer risk in SEAS study
1 September 2008
PDCO gives word on PIPs from latest meeting
1 September 2008
AstraZeneca's Crestor to be co-promoted with Abbott Labs in USA
1 September 2008
Germany's AOK tenders for more drug discounts
18 August 2008
FDA simvastatin with amiodarone warning
18 August 2008
Solvay's first-half 2008 profit declines 15%
11 August 2008
Greater LDL drop with "naturopathic" therapy
4 August 2008
Stock Commentary - New York week to July 21, 2008
28 July 2008
Merck & Co income still up despite low sales
28 July 2008
Patients more likely to stay on Pfizer's Lipitor than simvastatin, says managed care database study
21 July 2008
UPDATE: FDA panel votes in favor of outcomes over surrogate markers in diabetes drug approval
7 July 2008
Potential 5-year delay for US cholesterol pill
30 June 2008
Solvay's 1st-qtr 2008 net income rises 1%
26 May 2008
US drug spending curbed by generics
19 May 2008
New effort to curb DTC ads by US Democrats
12 May 2008
S-P profit down, sales up on Organon buy
5 May 2008
Merck & Co 1Q results saved by AZ payout
28 April 2008
Express Scripts' US health cost initiative
28 April 2008
Abbott reports 35% rise in earnings
28 April 2008
Rx-to-OTC switching making comeback
21 April 2008
Stock Commentary - New York week to April 7, 2008
14 April 2008
Class action against Merck & Co
14 April 2008
Schering-Plough plans $1.5B cost cuts due to market pressures and cholesterol drug woes
7 April 2008
Stock Commentary - New York week to March 31, 2008
7 April 2008
Crestor sales hopes raised by JUPITER trial
7 April 2008
Abbott's TriLipix improves key lipid measures
7 April 2008
Late-stage Cordaptive trial stalls on IMT issue
7 April 2008
Zetia "could be expensive placebo," ACC hears
7 April 2008
"Unknown" reason for EHANCE study failure
7 April 2008
Market slowdown for dyslipidemia drugs
31 March 2008
Abbott gets $100M under Simcor deal
24 March 2008
Stock Commentary - New York week to March 3, 2008
10 March 2008
Doctors claim statins cause memory loss
25 February 2008
Abbott's Simcor gets FDA approval as cholesterol control treatment
25 February 2008
US congressional committee widens Vytorin investigation
18 February 2008
S-P's 4th-qtr 2007 results hit by Organon buy
18 February 2008
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
